

Betula verrucosa (Itulazax®) - GP Information Sheet

Introduction

Betula verrucosa (Itulazax®) is a standardised allergen extract of pollen from white birch. It is an oral lyophilisate (melt) formulation, for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. By repeated administration of the allergen to allergic individuals, the immunological response to the allergen can be modified.

Patients will be assessed for suitability of treatment at the secondary care clinic, where indication for treatment, relevant co-morbidities etc. will be considered and the patient counselled on the medication and actions to take in the event of an allergic or adverse reaction.

Dosage and administration

The recommended dose for adult patients is one oral lyophilisate daily.

It should be taken with dry fingers from the blister pack and placed under the tongue, where it will disperse. Swallowing should be avoided for approximately 1 minute. Food and beverages should not be taken for the following 5 minutes

The first dose should be taken under medical supervision and the patient should be monitored for at least half an hour.

Treatment is usually initiated outside the pollen season and continued during the tree pollen season. A treatment duration of 3 years may be required to achieve disease modification.

If the treatment is interrupted for more than 7 days it is recommended to contact the specialist before restarting.

Available as

Itulazax oral lyophilisate in pack sizes of 30 and 90.

Monitoring requirements

The first oral lyophilisate should be taken in secondary care under medical supervision to enable the patient should be monitored for at least half an hour. Subsequent doses may be taken unsupervised.

Response to treatment will be assessed at secondary care clinic reviews. If no improvement is observed during the first year, treatment may be stopped.

Adverse effects, precautions and contraindications

Systemic allergic reactions, and worsening of the symptoms of existing oral allergy syndrome, are usually only expected at treatment initiation. Local allergic reactions of the upper respiratory system, oral pruritus, throat irritation, rhinitis, ear pruritus, and gastrointestinal disorders are common.

Common drug interactions

No interactions or no potential drug interactions have been identified but special caution/consideration should be given to commencing itulazax in patients who are already established on tricyclic antidepressants, MAOIs, COMT inhibitors, beta-blockers, and ACEI, due to the potential risk of attenuation of adrenaline if this is required for a severe systemic reaction.

Communication

For any queries relating to this patient's treatment with itulazax, please contact the specialist.

This information is not inclusive of all prescribing information and potential adverse effects.
Please refer to full prescribing data in the SPC or the BNF

Version:	Oct-2025-v1	Document Ref No:	SCG0072
Date Published:	October 2025	Date Updated:	Date of Review: October 2030